tbuckley/cabot-search huggingface dataset:
SAT0179 Efficacy and Safety of Rituximab in Patients with SLE And Systemic Vasculitides
Authors: S. Moiseev, P. Novikov, A. Meshkov, E. Kuznetsova, E. Zhabina, I. Lopatina, N. Bulanov
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Biologic agents are established treatment for rheumatoid arthritis while their efficacy in patients with systemic lupus erythematosus (SLE) and systemic vasculitides requires confirmation in additional studies. <h3>Objectives</h3> To evaluate the efficacy and safety of rituximab in patients with SLE and systemic vasculitides. <h3>Methods</h3> We enrolled in open-label uncontrolled trial all consecutive patients with severe SLE and systemic vasculitides that were treated with rituximab. Efficacy and safety of treatment was evaluated at 6 months using clinical and standard immunological criteria (eg. ANCA, ds-DNA, CRP) and specific scales (BVAS, SLEDAI):complete remission – resolution of activity and tapering of steroids, incomplete remission – significant improvement of signs and symptoms. <h3>Results</h3> During 3 years 57 patients were enrolled in 6-month trial: ANCA-associated vasculitides – 27 (granulomatosis with polyangitis [Wegener's] – 24, microscopic polyangitis – 2, Churg-Strauss syndrome – 1), SLE – 16, cryoglobulinemic vasculitis – 11, urticarial vasculitis – 1, Takayasu arteriitis – 1, giant cell arteritis – 1. All patients had severe visceral disease that was refractory to standard treatment including high dose cyclophosphamide and steroids. BVAS and SLEDAI scores averaged 16.8 and 11.2 points, respectively. The vast majority of patients responded to rituximab administration (500 mg weekly, 4 infusions). At 6 months complete and incomplete remission was achieved respectively in 17 (63.0%) and 9 (33.3%) patients with ANCA-associated vasculitides, 9 (56.3%) and 7 (43.7%) patients with SLE, 6 (54.5%) and 5 (45.5%) patients with cryoglobulinemic vasculitis, all patients with other vasculitides. In total 56 (98.2%) patients responded to rituximab at 6 months (complete remision in 59.6% of patients and incomplete remision in 38.6% of patietns). Average BVAS and SLEDAI scores have reduced to 1.6 and 3.2 points, respectively. The safety of rituximab was acceptable for patients with severe autoimmune disease who continued immunosuppresive treatment after biologic agent administration. Majority of adverse events were mild or moderately severe and did not require discontinuation of treatment. Serious adverse events were reported in 4 (7%) patients and included late neutropenia (in 2), severe infusion reaction (in 1) and death due to <i>Nocardia</i> sepsis (in 1). <h3>Conclusions</h3> Rituximab has favorable risk/benefit ratio in selected patients with severe SLE and ANCA-associated and crioglobulinemic vasculitides. Its efficacy in patients with other forms of vasculitides should be additionally studied. <h3>Disclosure of Interest</h3> None Declared
THE CHARACTERISTICS OF PATIENTS WITH ATRIAL FIBRILLATION IN WHICH 18F-FLUORODEOXYGLUCOSE ACCUMULATE IN THE ATRIAL WALL
Authors: Kiyotaka Okura, Hiroyuki Sugimoto, Seiichiro Okura, Hitoshi Takemori, Koji Maeno, Nobuyoshi Tanaka, Daishu Toya, Hose Iwasaki, Yasuo Takegoshi
Journal: Journal of the American College of Cardiology (2015)
APIXABAN VERSUS WARFARIN FOR PATIENTS WITH RECENT ONSET ATRIAL FIBRILLATION: INSIGHTS FROM THE ARISTOTLE TRIAL
Authors: Patricia Guimaraes, John Alexander, Daniel Wojdyla, Laine Thomas, Marco Alings, Greg Flaker, Sana Al-Khatib, Michael Hanna, Lars Wallentin, Christopher Granger, Renato Lopes
Journal: Journal of the American College of Cardiology (2016)
AB0253 The Relation between Pain and Inflammation in Early Rheumatoid Arthritis – Long-Term Follow up in the Swedish Population-Based EIRA and SRQ Register
Authors: M.E. Sandberg, R. Altawil, L. Alfredsson, L. Klareskog, S. Saevarsdottir, J. Lampa
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Pain is a hallmark symptom of RA and also widespread pain is relatively common in the disease. In order to optimize the respective pain and immune-suppressive treatment strategies, there is a need for more knowledge on long-term course of relations between pain and objective inflammation after RA diagnosis. <h3>Objectives</h3> To investigate the course of correlations between pain, disease activity, inflammation parameters and swollen/tender joints in early RA during clinical long-term follow-up. <h3>Methods</h3> We used the cases from a Swedish population-based case-control study; the EIRA study; 1802 incident RA patients aged 18-70 was recruited 1996-2009 and followed in the Swedish Rheumatology Quality register for up to 5 years. We calculated the correlation between pain at diagnosis, 3 months, 6 months, 12 months, 2 years and 5 years and DAS28 and its components at the same time points. <h3>Results</h3> The correlation between pain and the inflammation marker ESR decreased after diagnosis and was not statistically significant from 3 months and onwards, a similar pattern was found for the inflammation marker CRP (Figure 1). In contrast, the correlation between pain and both tender joint count, swollen joint count and patient global assessment (PGA) increased significantly after diagnosis. Tender joint count was significantly more correlated to pain than swollen joint count (swollen joint count correlation coefficient =0.31 [95%CI: 0.26-0.36] vs. tender joint count correlation coefficient =0.44 [95%CI: 0.40-0.48]). All correlations were very similar over calendar period and age at diagnosis and persisted also when patients not treated by DMARDS at diagnosis were excluded. <h3>Conclusions</h3> At diagnosis, pain in RA is correlated to both inflammation and clinical arthritis. Already after three months, our data show a loss of correlation between pain and objective inflammation, whereas we describe a stable and sustained correlation between pain and swollen and tender joints for the whole follow-up period of 5 years. These data corroborate the notion that the uncoupling of pain and inflammation may develop early after diagnosis and treatment initiation, and underscores the importance of a close monitoring of other causes of pain than joint inflammation. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.2126
SAT0358 The usefulness of vertebral fracture assessment in detecting prevalent vertebral fracture in patients with rheumatoid arthritis
Authors: J.-H. Lee, S.-K. Cho, M.-K. Han, J.-J. Kim, Y.-B. Joo, J.Y. Kim, S. Lee, J.A. Ryu, Y.Y. Choi, S.-C. Bae, Y.-K. Sung
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Osteoporosis is recognized as the main extra-articular complication of RA and results in an increased risk of fractures. It is important to detect vertebral fractures because they have been associated with increased risk of future vertebral and non-vertebral fractures, reduced quality of life, and increased morbidity and mortality. Vertebral morphometry using dual-energy X-ray absorption (DXA) also known as VFA is a convenient method of assess vertebral deformities, with low radiation and cost than morphometric radiography (MRX <h3>Objectives</h3> To validate VFA in the diagnosis of prevalent vertebral fractures in RA as compared to MRX and to evaluate availability of VFA in detecting vertebral fracture in RA patients according to the history of previous vertebral fractures or low back pain. <h3>Methods</h3> We prospectively enrolled 100 women with RA of 50 years or older and high risk of osteoporotic fracture. All participants had lateral imaging of thoracolumbar spine by VFA and MRX on the same day or within a few days. Also they completed questionnaires via interview about demographics, previous medical history, and medication. We calculated percent values for sensitivity and specificity of VFA with 95% confidence intervals in detecting vertebral fractures. The inter-rater reproducibility to vertebral fractures on VFA was evaluated by kappa statistics. Also the availability of VFA was evaluated in clinical practice according to the history of previous vertebral fracture or low back pain <h3>Results</h3> The prevalence of vertebral fracture identified by MRX was 47 patients (47%). Using VFA, 63 (VFA reader A) and 60 patients (reader B) had at least one vertebral fracture, respectively. The proportion of unreadable vertebrae was higher in VFA (5.3% in reader A and 12.2% in reader B) than in MRX (1.2%) and in upper thoracic vertebrae (T4-T8). Sensitivity and specificity of the diagnosis of fractures using VFA were 60-100% and 75-91% from T12 to L4 respectively. Interrater agreement for per vertebra by two VFA readers was moderate agreement at T9-L4 (k=0.4-0.7).All patients who had a history of vertebral fractures (N=13) were detected by both of MRX and VFA. However, 34 (34%) among 87 patients without vertebral fracture history were also detected occult fracture with MRX. Specificity of VFA for latter group by each readers were high in 94.0% (95% CI: 88.4-97.3%) and 91.4% (95% CI: 85.1-95.6%), while its sensitivity by each readers were low in 55.5% (95% CI: 38.1-72.1%) and 41.2% (95% CI: 29.4-53.8%), respectively. The presence of low back pain was not reliable history for detecting occult vertebral fracture. <h3>Conclusions</h3> Vertebral fracture assessment is a useful screening method for detecting occult vertebral fractures in RA patients <h3>Disclosure of Interest</h3> None Declared
Home Use of an Artificial Beta Cell in Type 1 Diabetes
Authors: Hood Thabit, Martin Tauschmann, Janet M. Allen, Lalantha Leelarathna, Sara Hartnell, Malgorzata E. Wilinska, Carlo L. Acerini, Sibylle Dellweg, Carsten Benesch, Lutz Heinemann, Julia K. Mader, Manuel Holzer, Harald Kojzar, Jane Exall, James Yong, Jennifer Pichierri, Katharine D. Barnard, Craig Kollman, Peiyao Cheng, Peter C. Hindmarsh, Fiona M. Campbell, Sabine Arnolds, Thomas R. Pieber, Mark L. Evans, David B. Dunger, Roman Hovorka
Journal: New England Journal of Medicine (2015)

The feasibility, safety, and efficacy of prolonged use of an artificial beta cell (closed-loop insulin-delivery system) in the home setting have not been established.
OP0232 Monitoring anti-interleukin 6 receptor antibody treatment in rheumatoid arthritis and prediction progressive structural damage of the wrist joints by ultrasonography:
Authors: A. Volkov, R. Osipyants, E. Panasyuk, A. Smirnov, G. Lukina, S. Gluchova, E. Aleksandrova, D. Karateev, E. Nasonov
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Objectives</h3> To evaluate the responsiveness of grey scale (GS) or power Doppler (PD) ultrasonography (US) compared with conventional measures of disease activity and to predict structural damage in patients (pts) with rheumatoid arthritis (RA) during 6 months of treatment with anti-IL 6 receptor antibody - tocilizumab (TCZ). <h3>Methods</h3> Pts with RA (N=46, median age 48.5 (range 39-55) years, disease duration 60 months, 83% “+” for RF and anti-CCP) were included at the start of treatment with TCZ. All pts were divided into two groups: 1st (n=11) – pts with disease duration &lt;2years, 2nd (n=36) – more two years. US (“Voluson-i” (GE, USA), 4-13MHz probe) was performed at baseline (n=46) and after 6 months (n=42), and included bilateral the wrist joints. Each joint was scored according to the OMERACT definitions of pathology [1]. Clinical (28 tender/swollen joints count (JC) and DAS28) and laboratory data (ESR, CRP) were obtained at each time of assessment. Standardized Response Means (SRM) were calculated for the changes of the variables over time (SRM = mean change/SD change). Accepted thresholds for effect size were applied to classify responsiveness as trivial, low, moderate or large. Hand, feet X-ray were performed at the entry and at one year. Radiographic progression was defined when the change of the van der Heijde-modified total Sharp score (Δ TSS) more than 0.5 units per year. <h3>Results</h3> SRM for change scores for US findings, clinical and laboratory data shown in the table. High responsiveness (&gt;0.80) for GS, PD scores were observed only pts with disease duration &lt;2 years as well as for swollen JC. Δ TSS (between M0 and M12) were significantly positively correlated with the PD score of the wrists at 6 months (r=0.669, p=0.008), but were not found correlations with the GS score and other markers of inflammatory. <h3>Conclusions</h3> US in GS and PD is a helpful tool in reflecting therapy response to TCZ (especially at pts with disease duration &lt;2 years). The PDUS score of the wrists at 6 months may be a good predictor of long-term radiographic damage. <h3>References</h3> Wakefield RJ, Balint PV, Szkudlarek M, Filippucci E, Backhaus M, D’Agostino M et al. Proceedings from the OMERACT Special Interest Group for Musculoskeletal Ultrasound including definitions for ultrasonographic pathology. J Rheumatol 2005; 32:2485-7. <h3>Disclosure of Interest</h3> None Declared
Abstract 3429: Mesenchymal hepatocellular carcinoma cells acquire cancer stem cell characteristics through Snail1
Authors: Hien Dang, Wei Ding, Hanning You, Dow Emerson, Carl B. Rountree
Journal: Cancer Research (2011)

Abstract Hepatocellular carcinoma (HCC) is the third leading cause of cancer mortality and the incidence of HCC is rising in the United States. Cancer stem cells (CSCs) are a subset of neoplastic cells that possess distinct survival mechanisms and plasticity crucial for tumor maintenance and propagation. The induction of epithelial-mesenchymal-transition (EMT) by Transforming Growth Factor-β (TGF-β) has been linked to the acquisition of CSC characteristics in breast cancer. In patients with HCC, either a CSC or EMT phenotype correlates with a worse prognosis. In this report, we aim to link EMT to CSCs and to further elucidate the mechanism by which cells acquire CSC characteristics during EMT. We utilized human (Huh7, MHCC97-L) and murine (P2E, P2M; Ding et al Hepatology. 2010) liver cancer cell lines, and analysis included gene and protein expression, FACS, migration and invasion assays, and chemotherapy resistance assay. Human mesenchymal MHCC97 cells demonstrate decreased E-cadherin, increased Snail1, and enhanced migration and invasion compared to epithelial Huh7 cells. MHCC97 cells demonstrate significant upregulation of stem cell markers (Oct4, Nanog, BMI-1, and CD44; p&amp;lt;0.01), increased CD44high population (95% vs. 2% Huh7, p&amp;lt;0.01), resistance to chemotherapy, resistance to TRAIL-induced apoptosis, increased tumor-sphere formation and slower cell cycle compared to epithelial Huh7 cells. We recently reported EMT in murine epithelial liver cell lines, P2E and P2M (post EMT). Mesenchymal P2M cells demonstrate loss of E-cadherin, gain of Snail1, increased tumor-sphere formation, and increased expression of stem cell markers (Nanog, Oct4, CD44, and EpCam; p&amp;lt;0.001). As TGF-β induces EMT through Snail1, we hypothesize that Snail1 signaling plays a role in the induction of an EMT and CSC phenotype in HCC. TGF-β treatment, epithelial P2E cells demonstrate fibroblastic-like morphology, 14-fold increase in Snail1 (p&amp;lt;0.01) and 8 fold increase in Nanog expression (p&amp;lt;0.01), increased tumor-sphere formation and migration. siRNA knockdown of Snail1 in mesenchymal P2M cells resulted in significant decrease in EMT and CSC characteristics, with decreased tumor-sphere formation, decreased migration, and decreased stem cell gene expression (Nanog and CD44, p&amp;lt;0.01). In conclusion, both murine and human mesenchymal HCC cells possess multiple CSC characteristics compared to epithelial counterparts. The transient knockdown of Snail1 in mesenchymal HCC cells results in the reversal of EMT as well as loss of CSC characteristics. We propose that Snail1 may play an important role in the regulation of EMT and CSC phenotypes. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3429. doi:10.1158/1538-7445.AM2011-3429
1971-1991: Quality of Life Gains Increased Attention
Authors: F. X. Mahaney
Journal: JNCI Journal of the National Cancer Institute (1991)

Journal Article 1971–1991: Quality of Life Gains Increased Attention Get access Francis X. Mahaney, Jr. Francis X. Mahaney, Jr. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 83, Issue 15, 7 August 1991, Pages 1052–1054, https://doi.org/10.1093/jnci/83.15.1052 Published: 07 August 1991
Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation
Authors: A Becherer, M Mitterbauer, U Jaeger, P Kalhs, HT Greinix, G Karanikas, C Pötzi, M Raderer, R Dudczak, K Kletter
Journal: Leukemia (2002)
LUNG ULTRASOUND WITH POCKET DEVICE MAY DETECT SUBCLINICAL CONGESTION IN AMBULATORY HEART FAILURE PATIENTS
Authors: Elke Platz, Eldrin Lewis, Julie M. Peck, Emanuele Pivetta, Allison A. Merz, Dorothea Hempel, Christina Wilson, Sarah E. Frasure, Susan Cheng, Scott Solomon
Journal: Journal of the American College of Cardiology (2015)
The significance of margin status in patients with DCIS undergoing breast-conserving surgery.
Authors: Rachel Gentile, Adam D. Currey, Jared Forrester, Bonifride Tuyishimire, Jonathan Lin, Amanda L. Kong
Journal: Journal of Clinical Oncology (2014)

98 Background: Recently, SSO/ASTRO published a consensus statement on margins for stage I and II invasive breast cancer treated with breast conserving surgery (BCS). We examined patients with ductal carcinoma in situ (DCIS) who underwent BCS to determine the effect of clinicopathologic and treatment factors including margin status, on locoregional recurrence (LRR), breast cancer-specific (BCSS) and overall survival (OS). Methods: From 2003-2010, we conducted a retrospective chart review of 253 consecutively diagnosed patients who underwent BCS for DCIS. Clincopathologic and treatment data were extracted. Margin status was defined by pathology reports with a negative margin as ≥ 2mm, close margin &lt; 2mm and positive margin as tumor on ink. Clinicopathologic variables were tested using the Fisher’s exact test, Chi-square test, ANOVA F-test, and Kruskal-Wallis test. A Cox proportional - Hazards model was used to calculate the impact of these factors on LRR, BCSS and OS. Results: The median age of the cohort was 57 (range 21-89) and the majority were white (79%), ER+ (78%) and underwent radiation therapy (67%). Forty six percent took anti-endocrine therapy. Of 252 patients, 29% had close margins, 63% had negative margins and 7% had unknown margins. One patient had a positive margin and was alive without disease at last follow-up. At a median follow-up of 5 years, OS was 96%. Thirteen patients experienced a LRR with a median time to recurrence of 4.9 years (5 with close margins, 7 with negative, 1 unknown). On multivariate analysis, age and PR status were significant predictors of LRR. Patients with age &gt;70 were more likely to recur than those age 50-69 (HR 6.7 95% CI (1.7-25.4) p= 0.005) as were patients with PR negative tumors (HR 5.7 95% CI (1.7-19.5) p= 0.005). Those patients who did not receive radiation therapy had a worse OS than those who did (HR 4.3 95%CI (1.5-12.6) p = 0.007). No variables were significant for BCSS. Conclusions: In this cohort of patients with DCIS treated with BCS, age and PR status were the only predictors of LRR. OS was only impacted by receipt of radiotherapy. Margin status was not predictive of LRR, BCSS or OS. This data suggests that routine re-excision for close margins may not be warranted.
Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy
Authors: Stephen J. Blake, Kimberley Stannard, Jing Liu, Stacey Allen, Michelle C.R. Yong, Deepak Mittal, Amelia Roman Aguilera, John J. Miles, Viviana P. Lutzky, Lucas Ferrari de Andrade, Ludovic Martinet, Marco Colonna, Kazuyoshi Takeda, Florian Kühnel, Engin Gurlevik, Günter Bernhardt, Michele W.L. Teng, Mark J. Smyth
Journal: Cancer Discovery (2016)

CD96 has recently been shown as a negative regulator of mouse natural killer (NK)-cell activity, with Cd96(-/-)mice displaying hyperresponsive NK cells upon immune challenge. In this study, we have demonstrated that blocking CD96 with a monoclonal antibody inhibited experimental metastases in three different tumor models. The antimetastatic activity of anti-CD96 was dependent on NK cells, CD226 (DNAM-1), and IFNγ, but independent of activating Fc receptors. Anti-CD96 was more effective in combination with anti-CTLA-4, anti-PD-1, or doxorubicin chemotherapy. Blocking CD96 in Tigit(-/-)mice significantly reduced experimental and spontaneous metastases compared with its activity in wild-type mice. Co-blockade of CD96 and PD-1 potently inhibited lung metastases, with the combination increasing local NK-cell IFNγ production and infiltration. Overall, these data demonstrate that blocking CD96 is a new and complementary immunotherapeutic strategy to reduce tumor metastases.This article illustrates the antimetastatic activity and mechanism of action of an anti-CD96 antibody that inhibits the CD96-CD155 interaction and stimulates NK-cell function. Targeting host CD96 is shown to complement surgery and conventional immune checkpoint blockade.
SAT0006 Microrna analysis of human lupus nephritis: Evidence for modulation of kallikrein 4 by MIR-422A
Authors: E. Krasoudaki, E. Stagakis, K. Loupasakis, A. Papagianni, E. Alexopoulos, G. Bertsias, D. Iliopoulos, D. Boumpas
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> In lupus, disease phenotype results from gene expression changes not only in the immune effector cells but also in the target organs. We have previously used miRNA analysis in the peripheral blood of patients with SLE in order to identify novel molecular pathways contributing to immune response deregulation. <h3>Objectives</h3> We sought to identify novel genes within the kidney in lupus nephritis by miRNA analysis. <h3>Methods</h3> We isolated RNA from renal biopsy samples of 12 subjects with proliferative or membranous lupus nephritis and 5 healthy controls. MiRNA expression was analysed by TaqMan Low Density Arrays (TLDA human miRNA v1.0). We used two different bioinformatic algorithms (TargetScan, PicTar) for the prediction of the gene targets of selected differentially expressed microRNAs. Validation of the miRNA-gene target interaction was performed by luciferase assay and real-time PCR analysis. MiRNA expression levels were assessed in kidney extracts from 2 months and 6 months lupus-prone (NZB/W F1) mice by real-time PCR. <h3>Results</h3> Compared to normal tissue a 24-miRNA signature defines human lupus nephritis with 9 miRNAs up-regulated and 15 miRNAs down-regulated, with miR-422a exhibiting the highest up-regulation (17.2-fold). Bioinformatic analysis predicted that miR-422a has a binding site in the 3'UTR of kallikrein 4 (KLK4) gene. This was validated by overexpression of miR-422a, which suppressed by 65% KLK4 luciferase activity and by 82% KLK4 mRNA levels in 293HEK cells. To monitor miR-422a/KLK4 expression during lupus nephritis progression, we used NZB/W F1 lupus mice. At early stages (2 months old NZB/W F1 mice) miR-422a was 4.1-fold up-regulated, while KLK4 mRNA levels were 3.4-fold down-regulated while at later stages (6 months) miR-422a was 9.4-fold up-regulated and KLK4 mRNA levels were 7.6-fold down-regulated. Ongoing experiments using antagomirs for miR-422 will further define its contribution to nephritis together with the construction of gene networks -by combining peripheral blood and renal microRNA data, are in progress. <h3>Conclusions</h3> The kallikrein family of genes has an important role in regulating inflammation, apoptosis, coagulation and fibrosis in the kidneys. Our data implicate KLK4, a secreted serine esterase with angiogenic and extracellular matrix remodeling properties in the pathogenesis of immune-mediated nephritis. <h3>Disclosure of Interest</h3> None Declared